ZD4054 (Zibotentan) in Pain-free or Mildly Symptomatic Patients With Prostate Cancer and Bone Metastases Who Have Rising Serum Prostate Specific Antigen (PSA)

PHASE2CompletedINTERVENTIONAL
Enrollment

447

Participants

Timeline

Start Date

July 31, 2004

Primary Completion Date

December 31, 2008

Study Completion Date

August 31, 2011

Conditions
Prostate Cancer
Interventions
DRUG

ZD4054 15 mg

15 mg oral tablet once daily

DRUG

Placebo

DRUG

ZD4054 10 mg

10mg oral tablet once daily

Trial Locations (60)

Unknown

Research Site, Tucson

Research Site, Los Angeles

Research Site, Gainsville

Research Site, Chicago

Research Site, Baltimore

Research Site, Cleveland

Research Site, Simpsonville

Research Site, Wolloongabba

Research Site, Ashford

Research Site, Wodonga

Research Site, Nedlands

Research Site, Brussels

Research Site, Ghent

Research Site, Leuven

Research site, Vancouver

Research site, London

Research site, Toronto

Research site, Montreal

Research site, Québec

Research Site, Aarhus

Research Site, Herlev

Research Site, Helsinki

Research Site, Joensuu

Research Site, OYS

Research Site, Seinäjoki

Research Site, Tampere

Research Site, Lille

Research Site, Montpellier

Research Site, Paris

Research site, Pontoise

Research Site, Toulouse

Research Site, Jakarta

Research Site, Eindhoven

Research Site, Groningen

Research Site, Heerlen

Research Site, Leiden

Research Site, Rotterdam

Research Site, Utrecht

Research Site, Bergen

Research Site, Fredrikstad

Research Site, Moelv

Research Site, Oslo

Research Site, Tromsø

Research Site, Trondheim

Research Site, Tønsberg

Research Site, Bydgoszcz

Research Site, Katowice

Research Site, Warsaw

Research Site, Gothenburg

Research Site, Malmo

Research Site, Stockholm

Research Site, Geneva

Research Site, Locarno

Research Site, Birmingham

Research Site, Leeds

Research Site, London

Research Site, Maidstone

Research Site, Manchester

Research Site, Newcastle

Research Site, York

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY